As a comparison, the proportions of CD3+T cells, CD14+ monocytes, and CD3-CD16+CD56+ NK cells in the lung cancer patients with the poorest immunological function were significantly different from those in the healthy control group (P <0.0001). This evidence concerns the gene CD14 and lung cancer.